Johns Hopkins researchers say they have found a specific protein in nearly 100 percent of high-grade meningiomas — the most common form of brain tumor — suggesting a new target for therapies for a cancer that does not respond to current chemotherapy.
Importantly, the investigators say, the protein — NY-ESO-1 — is already at the center of a clinical trial underway at the National Cancer Institute. That trial is designed to activate the immune systems of patients with other types of tumors that express the protein, training the body to attack the cancer and eradicate it.
{iframe}http://www.hopkinsmedicine.org/news/media/releases/johns_hopkins_researchers_find_promising_therapeutic_target_for_hard_to_treat_brain_tumor{/iframe}